Astellas Pharma: cross-border access for the specialty portfolio

Quick orientation

Astellas Pharma Inc. is a Japanese global pharmaceutical company headquartered in Tokyo with major US operations in Northbrook, Illinois. Astellas is a top-20 global pharma with strategic focus on oncology, urology, immunology, and ophthalmology, and is also building positions in cell therapy and regenerative medicine. The company is the developer or commercial owner of several blockbuster franchises including the androgen receptor antagonist Xtandi (with Pfizer), the menopause non-hormonal product Veozah, and the Claudin 18.2 targeted antibody Vyloy. Astellas trades on the Tokyo Stock Exchange. FDA approval scale spans approximately a dozen marketed products across its core therapeutic areas, with a strategic Primary Focus framework that prioritises differentiated specialty assets.

Astellas portfolio in cross-border NPP scope

Xtandi (enzalutamide), co-promoted with Pfizer, is an FDA-approved oral androgen receptor inhibitor for metastatic and non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and other prostate cancer settings. US list pricing is approximately US$14,500 per month. Oral dosing, once daily.

Veozah (fezolinetant) is an FDA-approved oral, non-hormonal neurokinin 3 receptor antagonist for moderate to severe vasomotor symptoms (hot flashes) associated with menopause (FDA approval May 2023). US list pricing is approximately US$550 per month. Veozah is the first FDA-approved non-hormonal therapy specifically for vasomotor symptoms with a mechanism targeted at the hypothalamic neurons that drive flushing.

Vyloy (zolbetuximab-clzb) is an FDA-approved Claudin 18.2-targeted monoclonal antibody for HER2-negative, CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (FDA approval October 2024). Vyloy is the first targeted therapy for Claudin 18.2-positive gastric cancer and is given in combination with chemotherapy.

Padcev (enfortumab vedotin), co-developed with Pfizer/Seagen, is an FDA-approved Nectin-4-directed antibody-drug conjugate for urothelial carcinoma, including in combination with pembrolizumab for first-line metastatic urothelial cancer.

Iclusig (ponatinib) is a BCR-ABL inhibitor for chronic myeloid leukemia and Philadelphia chromosome-positive ALL. Astagraf XL/Prograf (tacrolimus) and Mycamine (micafungin) are mature franchises typically with generic competition outside specific formulation niches.

Why patients route through cross-border NPP

Vyloy is the largest near-term cross-border NPP demand driver. Claudin 18.2 testing for gastric and GEJ adenocarcinoma is a new biomarker globally - it became standard of care in pathology workups only after Vyloy's October 2024 FDA approval and the European Commission approval in March 2024. Outside the United States and select EU markets, both Claudin 18.2 testing and Vyloy supply lag significantly. Confirmed-positive patients in the GCC, India, and Southeast Asia routinely have no local treatment option, and major gastric cancer referral centers have begun routine CLDN18.2 IHC testing in advance of local Vyloy availability.

Veozah serves a different cross-border profile. Hormone replacement therapy is not appropriate for women with a history of hormone-sensitive cancer (breast, endometrial), and Veozah is the first non-hormonal oral option with strong vasomotor symptom efficacy. Many international patients in this category specifically seek Veozah because their local market does not yet stock it. Cancer-survivor menopause clinics in the GCC and India are increasingly common referral sources.

Xtandi access is uneven outside major reimbursement markets. Generic enzalutamide is not yet available in the US, but parallel-import and counterfeit risk is high in some jurisdictions, making DSCSA-documented cross-border supply the safer route. Padcev for advanced urothelial cancer is similarly under-distributed outside major markets.

Common cross-border destinations

The highest-frequency NPP destinations for Astellas products from US-approved inventory are India, the United Arab Emirates, Saudi Arabia, Turkey, and Egypt. Major urology, oncology, and women's health centers in Mumbai, Bangalore, Dubai, Abu Dhabi, Riyadh, Istanbul, and Cairo drive most inbound referrals.

Manufacturer engagement posture

Reserve Meds coordinates Astellas-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with, owned by, or contracted as a distributor of Astellas Pharma. For Astellas US Oncology, Urology, or General Medicine commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each Astellas product request, Reserve Meds coordinates: prescription verification with the treating physician; biomarker documentation review where indicated (CLDN18.2 IHC for Vyloy, Nectin-4 expression where required for Padcev protocols); DSCSA serialized chain-of-custody from Astellas through licensed US wholesalers to the named patient; cold-chain shipping (2 to 8 degrees C) for Vyloy, Padcev, and other biologics with temperature data-loggers; ambient shipping for oral products such as Xtandi and Veozah; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients with a treating-physician prescription for an Astellas product can begin a request now. Start an Xtandi request › Start a Veozah request › Start a Vyloy request ›

Next step for Astellas teams

Astellas medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.